Skip to main content
. 2022 Mar 19;2022:9927240. doi: 10.1155/2022/9927240

Table 4.

Compliance among the three groups during 12 weeks of treatment.

MET group (n = 54) SPI group (n = 53) COM group (n = 51)
Nausea 6 (11.1%) 3 (5.88%) 5 (9.43%)
Diarrhea 3 (1.67%) 2 (3.92%) 3 (5.66%)
Vomiting 1 (1.85%) 0 1 (1.89%)
Polyuria 0 1 (1.96%) 0
Dry mouth 0 2 (3.92%) 0

MET: metformin; SPI: spironolactone; COM: combined.